An open-label, uncontrolled, multi-centre phase II study to investigate efficacy and safety of ONO-4538 in advanced melanoma patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 13 Nov 2017 Planned End Date changed from 1 Sep 2014 to 1 Jun 2020.
- 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2014 New trial record